Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.

Journal: Hospital practice (1995)

Volume: 49

Issue: 4

Year of Publication: 2021

Affiliated Institutions:  Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Malaysia. Department of Microbiology, Jahangirnagar University, Savar, Bangladesh. Resident, National Institute of Mental Health (NIMH), Dhaka, Bangladesh. Department of Endocrinology, Chittagong Medical College, Chattogram, Bangladesh. Department of Physiology, Eastern Medical College, Cumilla, Bangladesh. BIRDEM General Hospital, Shahbag Square, Dhaka, Bangladesh. Department of Endocrinology & Metabolism, Bangabandhu Sheik Mujib Medical University Hospital, Shahbag, Bangladesh. Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh. WISHACTION Project, Handicap International, Chamrargola, Kurigram Sadar, Kurigram, Bangladesh. Department of Obstetrics and Gynecology, Bangabandhu Sheik Mujib Medical University (BSMMU) Hospital, Shahbag, Bangladesh. Department of Endocrinology and Metabolism, Chattogram Maa-O-Shishu Hospital Medical College, Chattogram, Bangladesh. Department of Biochemistry, Medical College for Women & Hospital, Uttara, Bangladesh. World Fish, Banani, Bangladesh. Department of Biochemistry and Molecular Biology, Tejgaon College, National University of Bangladesh, Dhaka , Bangladesh. Department of Pharmacology & Therapeutics, Eastern Medical College, Cumilla, Bangladesh. Human Resource Department, Square Toiletries Limited, Rupayan Center, Bangladesh. Faculty of Dentistry, BSMMU, Bangladesh. Department of Anatomy, Eastern Medical College, Cumilla, Bangladesh. Department of Anatomy, Ad-din Women's Medical College, Dhaka, Bangladesh. Mario Negri Institute for Pharmacological Research, Milano, Italy. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.

Abstract summary 

Prevalence rates of patients with diabetes are growing across countries, and Bangladesh is no exception. Associated costs are also increasing, driven by costs associated with the complications of diabetes including hypoglycemia. Long-acting insulin analogues were developed to reduce hypoglycemia as well as improve patient comfort and adherence. However, they have been appreciably more expensive, reducing their affordability and use. Biosimilars offer a way forward. Consequently, there is a need to document current prescribing and dispensing rates for long-acting insulin analogues across Bangladesh, including current prices and differences, as a result of affordability and other issues.Mixed method approach including surveying prescribing practices in hospitals coupled with dispensing practices and prices among community pharmacies and drug stores across Bangladesh. This method was adopted since public hospitals only dispense insulins such as soluble insulins free-of-charge until funds run out and all long-acting insulin analogues have to be purchased from community stores.There has been growing prescribing and dispensing of long-acting insulins in Bangladesh in recent years, now accounting for over 80% of all insulins dispensed in a minority of stores. This increase has been helped by growing prescribing and dispensing of biosimilar insulin glargine at lower costs than the originator, with this trend likely to continue with envisaged growth in the number of patients. Consequently, Bangladesh can serve as an exemplar to other low- and middle-income countries struggling to fund long-acting insulin analogues for their patients.It was encouraging to see continued growth in the prescribing and dispensing of long-acting insulin analogues in Bangladesh via the increasing availability of biosimilars. This is likely to continue benefitting all key stakeholder groups.

Authors & Co-authors:  Haque Mainul M Islam Salequl S Kamal Zubair Mahmood ZM Akter Farhana F Jahan Iffat I Rahim Md Saghir Abdur MSA Sultana Nusrat N Alam Abm Muksudul AM Munzur-E-Murshid Halim-Khan M A MA Deeba Farzana F Bakar Muhammed Abu MA Nahar Shamsun S Mozaffor Miliva M Urmi Umme Laila UL Saikat Taohidur Rahman TR Islam Md Zakirul MZ Haque Monami M Iqbal Samiul S Hossain Mohammad Monir MM Naher Nurun N Allocati Eleonora E Godman Brian B

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  23
Identifiers
Doi : 10.1080/21548331.2021.1906083
SSN : 2154-8331
Study Population
Male,Female
Mesh Terms
Bangladesh
Other Terms
Biosimilars;bangladesh;diabetes;health policy;insulin glargine;insulins;prices;utilization
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
England